DDX56 Activators
DDX56 activators pertain to a class of chemical compounds that modulate the activity of the DEAD-box helicase 56 (DDX56) protein. DDX56 is part of the DEAD-box protein family, which is characterized by the presence of the conserved Asp-Glu-Ala-Asp (DEAD) motif. These proteins are putative RNA helicases implicated in various aspects of RNA metabolism, including transcription, RNA splicing, ribosome assembly, and the initiation of translation. As activators, these compounds interact with DDX56 to enhance its helicase activity or its interaction with other molecular components. The precise mechanisms by which DDX56 activators exert their effect on the protein can vary depending on the specific molecular structure of each compound and the context in which DDX56 is functioning. Typically, the activation might involve changes in the conformation of the protein, stabilization of the protein in an active state, or facilitation of protein-protein or protein-RNA interactions that are essential for helicase function.
Chemically, DDX56 activators can be diverse, ranging from small organic molecules to more complex biologically derived compounds. Their interaction with DDX56 is highly specific, often requiring precise molecular alignments to effectively engage with the protein's active sites or allosteric sites. This specificity is crucial for ensuring that the activation of DDX56 is well-regulated and does not indiscriminately affect the function of other helicases or cellular proteins. The molecular design of DDX56 activators can be influenced by the unique structural features of DDX56, such as its ATPase domain, which is integral for helicase activity, or its RNA-binding domains, which dictate the specificity of RNA substrate interaction. Understanding the structure-activity relationship (SAR) of these activators is essential to fine-tune their interaction with DDX56, optimizing the desired molecular effect while minimizing off-target interactions with other cellular components.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I, a protein kinase C (PKC) inhibitor, suppresses PKC activity. DDX56 is known to interact with PKC, and the inhibition of PKC by Bisindolylmaleimide I can disrupt downstream signaling, leading to enhanced DDX56 functional activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, a phosphoinositide 3-kinase (PI3K) inhibitor, affects the PI3K-AKT pathway. DDX56 interacts with components of this pathway. Wortmannin-mediated inhibition of PI3K leads to increased DDX56 functional activity by disrupting inhibitory signals and facilitating its activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580, a p38 MAP kinase inhibitor, impacts the p38 MAPK pathway. DDX56 is modulated by the p38 MAPK pathway, and inhibition by SB203580 enhances DDX56 activity. This compound prevents negative regulation of DDX56, resulting in increased functional activation through the p38 MAPK pathway. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib, a selective MEK inhibitor, interferes with the MAPK/ERK pathway. DDX56 is intricately linked to this pathway, and Trametinib enhances DDX56 functional activity by disrupting negative regulatory mechanisms within the MAPK/ERK pathway, leading to increased DDX56 activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, affects the JNK signaling pathway. DDX56 is known to interact with JNK pathway components. Inhibition by SP600125 enhances DDX56 functional activity by preventing negative feedback loops within the JNK pathway, resulting in increased activation of DDX56. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, a PI3K inhibitor, modulates the PI3K-AKT pathway. DDX56 interacts with components of this pathway. Inhibition by LY294002 enhances DDX56 activation by disrupting inhibitory signals within the PI3K-AKT pathway, leading to increased functional activity of DDX56. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059, a MEK inhibitor, influences the MAPK/ERK pathway. DDX56 is intricately linked to this pathway. Inhibition by PD98059 enhances DDX56 functional activity by disrupting negative regulatory mechanisms within the MAPK/ERK pathway, leading to increased activation of DDX56. | ||||||
VX 702 | 745833-23-2 | sc-361400 | 10 mg | $132.00 | 1 | |
VX-702, a p38 MAP kinase inhibitor, disrupts the p38 MAPK pathway. DDX56 is modulated by the p38 MAPK pathway, and inhibition by VX-702 enhances DDX56 functional activity. This compound prevents negative regulation of DDX56, resulting in increased activation through the p38 MAPK pathway. | ||||||
SP2509 | 1423715-09-6 | sc-492604 | 5 mg | $284.00 | ||
SP2509, a G9a histone methyltransferase inhibitor, influences epigenetic regulation. DDX56 expression can be epigenetically controlled. Inhibition by SP2509 enhances DDX56 functional activity by altering epigenetic marks, leading to increased expression and subsequent activation of DDX56. | ||||||